Literature DB >> 2868069

Organization of cytoskeleton elements during herpes simplex virus type 1 infection of human fibroblasts: an immunofluorescence study.

B Norrild, V P Lehto, I Virtanen.   

Abstract

Cultured human fibroblasts showed a typical fibrillar organization of microtubules in immunofluorescence, including the vimentin type of intermediate filament as well as actin-containing microfilaments. During infection with herpes simplex virus type 1 (HSV-1), the vimentin organization was maintained whereas actin, myosin and tubulin showed a progressive association with the viral glycoproteins within juxtanuclear structures. These structures could also be revealed with fluorochrome-coupled wheat germ agglutinin. Disruption of the microtubules by demecolcine treatment or their stabilization by taxol treatment did not prevent the aggregation of viral proteins in the cytoplasm. Taxol stabilization of the microtubules allowed the juxtanuclear accumulation of the glycoproteins in HSV-infected cells whereas treatment with demecolcine led to an accumulation of the glycoproteins either in small vesicles in the cytoplasm or in the focal adhesion areas of the cells. Production of infectious intracellular virus particles was reduced in cells treated with demecolcine or with taxol before and during infection. The results of this study indicate that the normal intracellular transport and distribution of the HSV glycoproteins and the formation of infectious virus are dependent on the presence of intact microtubules.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868069     DOI: 10.1099/0022-1317-67-1-97

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  17 in total

1.  Reconstitution of herpes simplex virus microtubule-dependent trafficking in vitro.

Authors:  Grace E Lee; John W Murray; Allan W Wolkoff; Duncan W Wilson
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

2.  Defining the cellular target(s) of porcine reproductive and respiratory syndrome virus blocking monoclonal antibody 7G10.

Authors:  Jeong-Ki Kim; Al-Majhdi Fahad; Kumar Shanmukhappa; Sanjay Kapil
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Replication of herpes simplex virus: egress of progeny virus at specialized cell membrane sites.

Authors:  Rebecca M Mingo; Jun Han; William W Newcomb; Jay C Brown
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Onset of human cytomegalovirus replication in fibroblasts requires the presence of an intact vimentin cytoskeleton.

Authors:  Matthew S Miller; Laura Hertel
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

5.  Simultaneous triple-immunogold staining of virus and host cell antigens with monoclonal antibodies of virus and host cell antigens in ultrathin cryosections.

Authors:  M H Nielsen; L Bastholm; S Chatterjee; J Koga; B Norrild
Journal:  Histochemistry       Date:  1989

6.  Evidence of a role for nonmuscle myosin II in herpes simplex virus type 1 egress.

Authors:  Hans van Leeuwen; Gill Elliott; Peter O'Hare
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Easy and reliable double-immunogold labelling of herpes simplex virus type-1 infected cells using primary monoclonal antibodies and studied by cryosection electron microscopy.

Authors:  H L Jensen; B Norrild
Journal:  Histochem J       Date:  1999-08

8.  Destabilization of herpes simplex virus type 1 virions by local anesthetics, alkaline pH, and calcium depletion.

Authors:  K Yanagi; S Harada
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

9.  Herpes simplex virus 1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes.

Authors:  Karen E Johnson; Leela Chikoti; Bala Chandran
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

10.  ICP0 dismantles microtubule networks in herpes simplex virus-infected cells.

Authors:  Mingyu Liu; Edward E Schmidt; William P Halford
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.